Pharmaceutical Business Review
Anonymous User | Login

Astrazeneca Terminates License Agreement With Map Pharmaceuticals

Published: 09-Jul-2009

UDB trial failed to meet its primary endpoints

AstraZeneca has terminated the license agreement with MAP Pharmaceuticals, regarding Unit Dose Budesonide (UDB).

UDB, an investigational treatment for paediatric asthma, was the subject of an initial phase-III clinical trial conducted by MAP Pharmaceuticals. On February 23, 2009, MAP announced that the trial failed to meet its primary endpoints.

In light of the clinical trial results, AstraZeneca exercised its right to terminate the license agreement and expects to record an impairment charge of $44 million in the second quarter results.

AstraZeneca is engaged in the research, development, manufacturing and marketing of prescription medicines and supplier for healthcare services. It is focused in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines.

MAP Pharmaceuticals is dedicated to developing and commercialising new therapies for children and adults suffering from chronic conditions.

Share

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

World Courier

Offering Fully-Integrated GxP-Compliant Global Transport and Storage for the Pharmaceutical Industry...

WebWise Learning

Turning Information into Working Knowledge ...

Vetter Pharma International

High-Quality Aseptically Pre-Filled Injection Systems, Cartridges and Vials ...

Valsynthese

Hazardous Chemistry in Safe Hands ...

USB

Products from Affymetrix ...

Umicore Precious Metals Chemistry

Chemicals and Catalysts for Industrial Applications ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Water Treatment

From the control room to the downstream processing area and with an eye on utilities servi ...

A Vaccinne Bioassay Case Study – A Successful Strategic Outsourcing Model

Increasingly, pharma and biotech firms are searching for new drivers of revenue and profit ...

USB HotStart-IT for Real Time PCR

USB® Products from Affymetrix have a long-standing reputation in the life science marketpl ...

Enabling Drug Delivery Deal Making

Transdermal drug delivery: Time for a closer look. To find out more download this free whi ...

Automating Training Control Processes to Comply with FDA Requirements

Well-managed training programs minimize the risk of non-compliance and improve product qua ...

TNO Pharma Services: From Discovery to the Clinic

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Related Companies

Forticell Bioscience, Inc.

Forticell Bioscience, Inc. (formerly Ortec International, Inc.) is engaged in the devel ...

MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals, Inc., (MAP) is a development stage company, engaged in the develo ...

AstraZeneca PLC

AstraZeneca PLC (AstraZeneca) is a leading pharmaceuticals company engaged in the desig ...

Boehringer Ingelheim GmbH

Boehringer Ingelheim GmbH (Boehringer) is a group of companies engaged in the research, ...

Merck & Co., Inc.

Merck & Co., Inc. (Merck) is a global research-driven pharmaceutical company engaged in ...

Suppliers Product News

World Courier CTSCS Depots Provide Dedicated Storage for GMO Products

In response to growing client demand and based on recently-established international biosafety regulations, World Courier has begun rolling out dedicated storage areas for GMO-derived pharmaceutical products throughout its global investigational drug storage network.

World Courier Triples Clinical Trial Storage Capacity Worldwide with Two New Facilities and Client-Driven Expansion

World Courier expands its GMP-compliant Clinical Trial Supply Chain Services (CTSCS) network, facilitating access to growing pharmaceutical markets in Africa and Australia.

World Courier Achieves Coveted GxP-Compliant Status Worldwide with Focus on GDP, Quality Management

With a fully GxP-compliant transport and supply chain system in place, World Courier meets the most demanding industry requirements for managing time- and temperature-sensitive clinical trial materials used in global studies.

Vetter Dedicates New Facility in Suburban Chicago

The new facility will enable collaboration very early in development process

Pharma Supplier Vetter Shares Pride in Consistent Growth and International Success with Distinguished Visitor Minister zu Guttenberg

Economics and Technology Minister visits global leader's headquarters in southern Germany.

Vetter Packages Success with New Facility

Vetter's new secondary packaging operation allows the company to double its production in half the time.

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address